5 stories mentioning SGMTUpdated 15d ago
Every FINWIRES story that references SGMT, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Sagimet Biosciences (SGMT) has an average rating of buy and mean price target of $29.33, according to analysts polled by FactSet.
Sagimet Biosciences (SGMT) is making "good progress" in advancing denifanstat as a treatment for moderate to severe acne for the US market, Wedbush Securities said in a note Tuesday.The investment firm said positive data from studies conducted in China suggest limited clinical risk for the experimental therapy, which is expected to enter phase 3 testing in H2 after regulatory clearance.The company expects fast patient enrollment in the phase 3 study, with topline data possible by the end of 2027 or in early 2028, according to the note.Wedbush said Sagimet ended Q2 with $257.6 million in cash after raising $175 million in April, with its cash runway expected to extend through 2028 and beyond the anticipated denifanstat phase 3 readout.The firm said recent investor discussions reinforced the view that Sagimet remains "deeply undervalued" and continues to offer significant upside despite recent share gains.Wedbush Securities has an outperform rating on Sagimet Biosciences, with a price target of $28.Price: $9.56, Change: $-0.01, Percent Change: -0.10%
Sagimet Biosciences (SGMT) has joined the Russell 3000 and Russell 2000 indexes, effective Monday, as part of the 2026 Russell Indexes reconstitution, the company said on the same day.The company said it has capital in place to fund its programs through 2028, including a planned phase 3 trial of denifanstat in moderate to severe acne, expected in H2.Price: $7.20, Change: $+0.14, Percent Change: +1.91%
Sagimet Biosciences (SGMT) has an average rating of buy and mean price target of $27, according to analysts polled by FactSet.Price: $7.93, Change: $-0.11, Percent Change: -1.31%
Sagimet Biosciences (SGMT) said Monday it has priced an underwritten offering of about 29.2 million shares at $6.00 each to raise about $175 million to help fund its clinical trial.Shares soared 43% as intraday trading volume catapulted to over 45.2 million from a daily average of about 516,000.Veradermics (MANE) said Monday part A of its phase 2/3 trial of VDPHL01 oral pill in males with mild-to-moderate pattern hair loss met all primary and all key secondary endpoints with "high" statistical significance.Shares surged 32%, with intraday trading volume of over 2.5 million from a daily average of roughly 446,000.Oruka Therapeutics (ORKA) jumped 16% after the company said Monday almost 64% of patients treated with ORKA-001 achieved the primary endpoint of complete skin clearance at week 16 in a phase 2a trial in moderate-to-severe plaque psoriasis.More than 5.10 million shares traded intraday, compared with a daily average of about 760,000.Price: $8.36, Change: $+2.50, Percent Change: +42.58%
